Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2025 | Looking forward to ISAL 2025

Marion Subklewe • 21 Jan 2025
ISAL 2025
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia

Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, shares her excitement for the 19th International Symposium on Acute Leukemias (ISALXIX), taking place on March 16-19, 2025, in Munich, Germany. The program features cutting-edge topics ranging from basic science and translational research to clinical applications in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Marion Subklewe

AVC-201: a CAR-T using a switchable module in AML
13:39
AVC-201: a CAR-T using a switchable module in AML
Marion Subklewe • 19 Sep 2026
Emerging immunotherapy strategies in AML: CAR-T, NK cells and T-cell engagers
17:01
Emerging immunotherapy strategies in AML: CAR-T, NK cells and T-cell engagers
David Sallman et al. • 20 Sep 2026
The GoCART Observership Programme: promoting knowledge transfer & building a European CAR-T network
1:46
The GoCART Observership Programme: promoting knowledge transfer & building a European CAR-T network
Marion Subklewe • 24 Mar 2026
Factors contributing to the reduction in the incidence of higher-grade CRS and ICANS
4:06
Factors contributing to the reduction in the incidence of higher-grade CRS and ICANS
Marion Subklewe • 24 Mar 2026

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals